Less Toxic Chemotherapy in Locally Advanced Breast Cancer.

ABSTRACT:

Objectives

Preoperative chemotherapy produces tumor shrinkage in most patients with locally advanced breast cancer, including some pathological complete responses (pCRs). We attempted this using a much less toxic sequential regimen, given with concurrent bevacizumab.

Methods

Patients with locally advanced breast cancer received 3 intravenous doses each of preoperative sequential liposome encapsulated doxorubicin 25 mg/m², paclitaxel 175 mg/m², and cyclophosphamide 600 mg/m², with concurrent bevacizumab every 2 weeks without growth factor support.

Results

Between March 2008 and December 2009, 32 patients received treatment. There was no cardiotoxicity, and other toxicity was mild (no grade 4 or 5 toxicity). No long-term toxicity, includ

SUBMITTER: Carpenter J 

PROVIDER: S-EPMC8787856 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature